Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allied BiotechROCO:1780 +1.57%77 Pretax Margin % is 30.20% as of Dec. 2025, which is 81% above its 10-year median of 16.71. GuruFocus rates ROCO:1780 with a GF Score™ of 77/100 and a GF Value™ of NT$20.78 (Fairly Valued). The stock has 5 warning signs investors should review. Among 959 Drug Manufacturers companies, Allied Biotech ranks better than 79.87% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Allied Biotech's Pre-Tax Income for the
three
months ended in Dec. 2025 was NT$64.6 Mil. Allied Biotech's Revenue for the
three
months ended in Dec. 2025 was NT$213.9 Mil. Therefore, Allied Biotech's pretax margin for the quarter that ended in Dec. 2025 was 30.20%.
The historical rank and industry rank for Allied Biotech's Pretax Margin % or its related term are showing as below:
ROCO:1780'
s Pretax Margin % Range Over the Past 10 Years
Min: 2.6 Med: 16.71 Max: 25.82
Current: 19.32
ROCO:1780's Pretax Margin % is ranked better than 79.87% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.29
vs ROCO:1780: 19.32
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Allied Biotech Pretax Margin % Related Terms
Allied Biotech Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Allied Biotech's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1780 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Allied Biotech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allied Biotech Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allied Biotech's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Allied Biotech's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allied Biotech (ROCO:1780) has a Pretax Margin % of 30.20% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Allied Biotech and its competitors. This is 81% above median its historical median of 16.71. Over the past decade, Allied Biotech's Pretax Margin % has ranged from 2.60 to 25.82. According to the industry distribution chart, Allied Biotech ranks #193 out of 959 companies in the Drug Manufacturers industry, placing it in the top 20.1%.
Is Allied Biotech's Pretax Margin % too high?
Allied Biotech's current Pretax Margin % of 30.20% is 81% above median its 10-year median of 16.71. Over the past 10 years, this metric has ranged from a low of 2.60 to a high of 25.82. The Drug Manufacturers industry median Pretax Margin % is 7.29. Allied Biotech's value of 30.20% is 314.3% above this industry median. Based on the distribution chart, Allied Biotech ranks #193 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Allied Biotech has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Allied Biotech's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allied Biotech ranks #193 out of 959 companies for Pretax Margin %. This places Allied Biotech in the top 20% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.29. Allied Biotech's value of 30.20% is 314.3% above this benchmark. Historically, Allied Biotech's own Pretax Margin % has ranged from 2.60 to 25.82 over the past decade. While the company's 10-year median is 16.71 vs. the industry median of 7.29, Allied Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allied Biotech's current Pretax Margin % of 30.20% is 314.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Allied Biotech and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allied Biotech's current Pretax Margin % is 30.20%, which is 81% above median its own 10-year median of 16.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied Biotech stock overvalued right now?
Based on GuruFocus' analysis, Allied Biotech (ROCO:1780) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.78, compared to a current price of NT$22.65 — trading 9% above its estimated fair value. The current Pretax Margin % is 30.20%, which is 81% above median its 10-year median of 16.71 and 314.3% above the Drug Manufacturers industry median of 7.29. Allied Biotech's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Allied Biotech (ROCO:1780), the current Pretax Margin % is 30.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allied Biotech (ROCO:1780) Overvalued in 2026?
Based on GuruFocus' analysis, Allied Biotech stock appears to be overvalued.
The current stock price of NT$22.65 is trading 9% above its estimated GF Value™ of NT$20.78.
GuruFocus considers Allied Biotech to be Fairly Valued.
Key valuation signals for ROCO:1780:
Pretax Margin %: 30.20% (81% above median its 10-year median of 16.71)
GF Value™: NT$20.78 vs. price of NT$22.65 (9% above fair value)
Industry Position: 314.3% above the Drug Manufacturers median (#193 of 959)
No single metric tells the full story. See the ROCO:1780 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allied Biotech Corp is a Taiwan based manufacturer of carotenoids. It manufactures carotenoid formulations for the food, supplement and feed industries. The company markets its products under the name Altratene.
77GF Score
Get the complete analysis for ROCO:1780
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1780 has been successfully added to your 
